Your SlideShare is downloading. ×
BCC4: Clive Woolfe on Chronic Liver Disease
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

BCC4: Clive Woolfe on Chronic Liver Disease

733
views

Published on

Clive Woolfe, Irishman and RPA Intensivist, speaks at Bedside Critical Care Conference. In this podcast, he gives an overview of the prognostication and management of chronic liver disease. See …

Clive Woolfe, Irishman and RPA Intensivist, speaks at Bedside Critical Care Conference. In this podcast, he gives an overview of the prognostication and management of chronic liver disease. See www.intensivecarenetwork.com for the podcast.

Published in: Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
733
On Slideshare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
10
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Chronic Liver Disease BCC, Cairns, September 2013 Clive Woolfe
  • 2. Definitions Organ
  • 3.   Support Prognositicating... Facts
  • 4.   and
  • 5.   Figures
  • 6. Cirrhosis “late stage of progressive hepatic fibrosis” Death from Portal Hypertension, progressive MOF, not encephalopathy
  • 7. The economic cost and health burden of liver disease in Australia January 2013
  • 8. Child-Turcotte-Pugh Abdominal Surgery Mortality (%) ! 10 ! 30 ! 82
  • 9. MELD Model for Endstage Liver Disease 9.57 x ln(Creatinine) + 3.78 x ln(Bilirubin) +11.2 x In(INR) + 6.43
  • 10. MELD Model for Endstage Liver Disease 9.57 x ln(Creatinine) + 3.78 x ln(Bilirubin) +11.2 x In(INR) + 6.43 20 40 60 80 100 0 10 15 20 25 30 40 83 80 78 74 71 90 81 63 42 21 Waiting List Survival 1 year post OLTx Survival MELD Score %
  • 11. Terminal Disease... progressive MOF
  • 12. ICU
  • 13. ICU Reversible precipitant? ! Organ support as a bridge to transplant
  • 14. Precipitants Look for Reversibility Drugs BDZ Narcotics Ammonia Diet Infection GI bleeding Hypokalaemia Constipation Metab Alkalosis Vascular Occlusion Porto-systemic shunts NH3 Dehydration V&D Hemorrhage Diuretics Paracentesis HCC Alcohol
  • 15. Variceal Haemorrhage Median Follow Up 2.5 years
  • 16. No survival advantage 2x Encephalopathy ?
  • 17. Organ support
  • 18. Neurological NH3 Serial Examination Hippus Clonus Hyperreflexia
  • 19. Efficacy of “Treatments” for HE +
  • 20. Respiratory Bleeding Sepsis ?Hepato-pulmonary Syndrome Porto-Pulmonary Hypertension PAP Massive TidalVolumes Paracentesi
  • 21. CVS E. Coli
  • 22. Renal/Fluids Renal hypoperfusion RAA activation Low Intravascular Volume vs. High TBW Hepatic CongestionHepatorenal Syndrome Late presentation: Low muscle mass Low urea production “Euvolaemia”
  • 23. Gastrointestinal
  • 24. Precipitating Event SBP Prophylaxis Sepsis ! 24% of cirrhotic inpatients RTI > UTI > C.Diff Mortality increase: 39 to 49%
  • 25. Finally... ICU Reversible precipitant? ! Organ support as a bridge to transplant
  • 26. ICU Reversible precipitant? ! Organ support as a bridge to transplant